Divergence Among EU and US Advisers on AstraZeneca's Breast Cancer Treatment
Recent discussions reveal a split between EU and US advisers regarding AstraZeneca's breast cancer drug, amid notable developments in other biotech areas.
Editorial Staff
1 min read
Updated 18 days ago
AstraZeneca's breast cancer drug has become a point of contention between advisers in the EU and the US, highlighting differing perspectives on its efficacy and approval.
In related news, Merck-Kelun's antibody-drug conjugate (ADC) has reportedly outperformed Keytruda in clinical trials, suggesting a potential shift in treatment options.
Additionally, a closely monitored Parkinson’s drug has failed to meet expectations, raising concerns about its future in the market.